• 文献检索
  • 文档翻译
  • 深度研究
  • 学术资讯
  • Suppr Zotero 插件Zotero 插件
  • 邀请有礼
  • 套餐&价格
  • 历史记录
应用&插件
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
定价
高级版会员购买积分包购买API积分包
服务
文献检索文档翻译深度研究API 文档MCP 服务
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利：CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2026

文献检索

告别复杂PubMed语法，用中文像聊天一样搜索，搜遍4000万医学文献。AI智能推荐，让科研检索更轻松。

立即免费搜索

文件翻译

保留排版，准确专业，支持PDF/Word/PPT等文件格式，支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述，25分钟生成高质量综述，智能提取关键信息，辅助科研写作。

立即免费体验

A response to "In response to 'Sodium-glucose cotransporter 2 inhibitors and inflammation in chronic kidney disease: Possible molecular pathways'".

作者信息

Yaribeygi Habib, Katsiki Niki, Butler Alexandra E, Atkin Stephen L, Sahebkar Amirhossein

机构信息

Chronic Kidney Disease Research Center, Shahid Beheshti University of Medical Sciences, Tehran, Iran.

Second Propedeutic Department of Internal Medicine, Medical School, Aristotle University of Thessaloniki, Hippokration Hospital, Thessaloniki, Greece.

出版信息

J Cell Physiol. 2019 Jul;234(7):9908-9909. doi: 10.1002/jcp.28041. Epub 2019 Feb 2.

DOI:10.1002/jcp.28041
PMID:30710347
Abstract
摘要

相似文献

1
A response to "In response to 'Sodium-glucose cotransporter 2 inhibitors and inflammation in chronic kidney disease: Possible molecular pathways'".
J Cell Physiol. 2019 Jul;234(7):9908-9909. doi: 10.1002/jcp.28041. Epub 2019 Feb 2.
2
In response to Yaribeygi et al. "Sodium-glucose cotransporter 2 inhibitors and inflammation in chronic kidney disease: Possible molecular pathways".
J Cell Physiol. 2019 Jul;234(7):9906-9907. doi: 10.1002/jcp.28235. Epub 2019 Jan 29.
3
Renal and Cardiac Implications of Sodium Glucose Cotransporter 2 (SGLT2) Inhibitors: The State of the Science.钠-葡萄糖共转运蛋白 2（SGLT2）抑制剂的肾脏和心脏影响：科学现状。
Ann Pharmacother. 2018 Dec;52(12):1238-1249. doi: 10.1177/1060028018783661. Epub 2018 Jun 17.
4
Sodium glucose cotransporter 2 inhibition and renal ischemia: implications for future clinical trials.钠-葡萄糖协同转运蛋白 2 抑制与肾缺血：对未来临床试验的影响。
Kidney Int. 2018 Sep;94(3):459-462. doi: 10.1016/j.kint.2018.05.026.
5
Possible Mechanism of Hematocrit Elevation by Sodium Glucose Cotransporter 2 Inhibitors and Associated Beneficial Renal and Cardiovascular Effects.钠-葡萄糖协同转运蛋白2抑制剂导致血细胞比容升高的可能机制及相关的肾脏和心血管有益效应
Circulation. 2019 Apr 23;139(17):1985-1987. doi: 10.1161/CIRCULATIONAHA.118.038881.
6
Chinese expert consensus on the clinical application of sodium-glucose cotransporter 2 inhibitors in patients with chronic kidney disease.慢性肾脏病患者应用钠-葡萄糖协同转运蛋白2抑制剂的中国专家共识
Chin Med J (Engl). 2024 Jun 5;137(11):1264-1266. doi: 10.1097/CM9.0000000000003145. Epub 2024 May 13.
7
Clinical Credence - SGLT2 Inhibitors, Diabetes, and Chronic Kidney Disease.临床可信度——钠-葡萄糖协同转运蛋白2抑制剂、糖尿病与慢性肾脏病
N Engl J Med. 2019 Jun 13;380(24):2371-2373. doi: 10.1056/NEJMe1904740. Epub 2019 Apr 14.
8
Optimizing SGLT inhibitor treatment for diabetes with chronic kidney diseases.优化用于慢性肾脏病糖尿病患者的钠-葡萄糖协同转运蛋白抑制剂治疗
Biol Cybern. 2019 Apr;113(1-2):139-148. doi: 10.1007/s00422-018-0765-y. Epub 2018 Jun 28.
9
Canagliflozin reduced kidney failure and CV events at 2.6 years in type 2 diabetes with chronic kidney disease.在患有慢性肾病的2型糖尿病患者中，卡格列净在2.6年时降低了肾衰竭和心血管事件的发生率。
Ann Intern Med. 2019 Aug 20;171(4):JC15. doi: 10.7326/ACPJ201908200-015.
10
Response by Kosiborod et al to Letters Regarding Article, "Lower Risk of Heart Failure and Death in Patients Initiated on Sodium-Glucose Cotransporter-2 Inhibitors Versus Other Glucose-Lowering Drugs: The CVD-REAL Study (Comparative Effectiveness of Cardiovascular Outcomes in New Users of Sodium-Glucose Cotransporter-2 Inhibitors)".科西博罗德等人对关于“与其他降糖药物相比，起始使用钠-葡萄糖协同转运蛋白2抑制剂的患者心力衰竭和死亡风险更低：CVD-REAL研究（钠-葡萄糖协同转运蛋白2抑制剂新使用者心血管结局的比较有效性）”一文的信件的回复
Circulation. 2018 Feb 27;137(9):989-991. doi: 10.1161/CIRCULATIONAHA.117.031847.

引用本文的文献

1
Biological and Therapeutic Effects of Troxerutin: Molecular Signaling Pathways Come into View.曲克芦丁的生物学及治疗作用：分子信号通路渐趋明晰。
J Pharmacopuncture. 2021 Mar 31;24(1):1-13. doi: 10.3831/KPI.2021.24.1.1.